Trials / Unknown
UnknownNCT03766919
Safety and Electrical Performance Evaluation of INVICTA Leads Models Equipped With DF4 Connector
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- MicroPort CRM · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and key electrical performance of the INVICTA leads equipped with DF4 connector: ACTIVE fixation type models (single and dual coil: INVICTA 1CR, INVICTA 2CR) and PASSIVE fixation type models (single and dual coil: INVICTA 1CT, INVICTA 2CT).
Detailed description
FRIENDS study is a pre-market approval (INVICTA leads - devices under investigation - are not CE marked), interventional, prospective, longitudinal, international (European), multicenter, single arm study. The devices under investigation, the INVICTA defibrillation leads, are new quadripolar leads, to be used with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators (ICD/CRT-D). This clinical study intends to demonstrate safety and electrical performances of the INVICTA leads among the different models: active fixation either single coil (model 1CR) or dual coil (model 2CR) and passive fixation, either single coil (model 1CT) or dual coil (model 2CT) leads models. The clinical data will be used to support the application to CE marking of INVICTA leads. The primary endpoints will be evaluated at 3 months post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. A maximum number of 224 patients will be enrolled in the study, in up to 60 centers in Europe. The follow-up visits are scheduled at hospital discharge, at 1 month, at 3 months, at 6 months, at 12 months, at 18 months and at 24 months, post-implant .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Implant of the INVICTA lead | The implant or the attempt to implant an INVICTA lead |
Timeline
- Start date
- 2018-12-27
- Primary completion
- 2020-03-01
- Completion
- 2021-03-01
- First posted
- 2018-12-06
- Last updated
- 2019-04-16
Locations
10 sites across 4 countries: France, Italy, Portugal, Spain
Source: ClinicalTrials.gov record NCT03766919. Inclusion in this directory is not an endorsement.